2.60Open2.60Pre Close0 Volume0 Open Interest7.00Strike Price0.00Turnover349.14%IV-6.80%PremiumDec 20, 2024Expiry Date2.88Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5928Delta0.1152Gamma1.17Leverage Ratio-0.0323Theta-0.0028Rho-0.69Eff Leverage0.0038Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet